CytoDyn will be hosting a webcast on May 5th to provide updates for several company initiatives

Vancouver

VANCOUVER, Wash., May 3, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix ™ (leronlimab-PRO 140)) , a CCR5 antagonist with potential for multiple therapeutic indications, announced today that Dr. Nader Pourhassan, President and Chief Executive Officer, Dr. Scott Kelly, Chairman and Chief Medical Officer, and Dr. Chris Recknor, Chief Operating Officer, will host a webcast from the investment community on Wednesday, May 5th, 2021.

Management will fully inform its shareholders of the company’s priorities, including recent COVID-19 initiatives and additional information on its active studies on COVID-19, NASH and cancer.

Management will allow approximately 60 minutes to answer questions submitted online by analysts and investors.

Date: Wednesday, May 5, 2021 Time: 1:00 p.m. PT / 4:00 p.m. ET Dial-in: None. Ask:

Questions can be submitted online prior to the webcast to

Questions may be submitted during the webcast using the webcast link below.

This is a “listen only” webcast that can be accessed via the CytoDyn corporate website at www.cytodyn.com in the Investors / IR Calendar section and is archived for 30 days. Attendees are encouraged to go to the website 15 minutes before the webcast begins to register, download, and install the required software. Please note that the webcast link below is only operational approx. 60 minutes before the start of the webcast and can be accessed via the following link:

The replay will be available approximately 60 minutes after the webcast closes and can be accessed through the link above until June 5, 2021.